Clearsense

About Clearsense

Clearsense offers a Platform-as-a-Service (PaaS) solution tailored for the healthcare industry, focused on transforming complex data into actionable insights to improve patient outcomes and operational efficiency. The company was co-founded in 2015 by Jason Mabry, Gene Scheurer, and Charles Boicey, individuals with deep experience in technology, healthcare, and data analytics. The founders identified data scarcity and latency as significant obstacles for clinicians and established the company to address these challenges. Charles Boicey, who serves as the Chief Innovation Officer, brought extensive experience as a registered nurse and enterprise analytics architect at Stony Brook Medicine. His background in clinical informatics and early work in data analytics, such as developing an award-winning application for disease outbreak detection using social media, shaped the company's direction.

The company's core offering is the 1Clearsense Data Management Platform, a cloud-native system designed to integrate and unify data from disparate sources, including electronic health records (EHRs), financial systems, and legacy applications. This platform serves a client base that includes large integrated delivery networks, health systems, academic medical research centers, and payers. Clearsense generates revenue through a subscription-based model, which makes its advanced analytics accessible to a broader range of healthcare providers, including smaller and rural hospitals that might not afford large upfront capital investments. By centralizing data, the platform aims to create a single source of truth, enabling better data governance, transparency, and decision-making.

The 1Clearsense platform features two primary solutions: ReviveCS and RevealCS. ReviveCS is an enterprise data archiving solution that helps health systems decommission costly legacy applications while keeping historical data accessible within current workflows. This process has reportedly saved client organizations tens of millions of dollars. RevealCS functions as a healthcare data lakehouse, providing a comprehensive, longitudinal view of patient data. This solution supports advanced applications such as AI model training, quality measure calculations, and significantly accelerates clinical trial matching by reducing the time to identify patient cohorts from months to minutes. A key feature is the "Bring Your Own Technology" (BYOT) approach, allowing researchers to use their preferred tools for analysis. The company has achieved significant milestones, including raising a total of $124 million over seven funding rounds and acquiring the AI analytics firm Compellon to enhance its platform's capabilities.